The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic

Archives of Internal Medicine

Volumn 163, Issue 9, 2003, Pages 1009-1021

  Corbett, Elizabeth L ^a   Watt, Catherine J ^b   Walker, Neff ^c   Maher, Dermot ^b   Williams, Brian G ^b   Raviglione, Mario C ^b   Dye, Christopher ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UNAIDS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; EPIDEMIC; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; PREVALENCE; REGISTRIES; TUBERCULOSIS; TUBERCULOSIS, PULMONARY; WORLD HEALTH;

EID: 0012746992     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.9.1009     Document Type: Review

References (128)

1. Bucher HC, Griffith LE, Guyatt GH, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS. 1999;13:501-507.
2. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med. 1992;326:231-235.
3. Shafer RW, Singh SP, Larkin C, Small PM. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in an immunocompetent patient. Tuber Lung Dis. 1995;76:575-577.
4. Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res. 1976;19:1-63.
5. Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect. 1997;119:183-201.
6. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320:545-550.
7. Girardi E, Raviglione MC, Antonucci G, Godfrey-Faussett P, Ippolito G. Impact of the HIV epidemic on the spread of other diseases: the case of tuberculosis. AIDS. 2000;14(suppl 3):S47-S56.
8. Cantwell MF, Binkin NJ. Tuberculosis in sub-Saharan Africa: a regional assessment of the impact of the human immunodeficiency virus and National Tuberculosis Control Program quality. Tuber Lung Dis. 1996;77:220-225.
9. Raviglione MC, Harries AD, Msiska R, Wilkinson D, Nunn P. Tuberculosis and HIV: current status in Africa. AIDS. 1997;11(suppl B):S115-S123.
10. Wilkinson D, Davies GR. The increasing burden of tuberculosis in rural South Africa: impact of the HIV epidemic. S Afr Med J. 1997;87:447-450.
11. Churchyard GJ, Kleinschmidt I, Corbett EL, Mulder D, De Cock KM. Mycobacterial disease in South African gold miners in the era of HIV infection. Int J Tuberc Lung Dis. 1999;3:791-798.
12. Kenyon TA, Mwasekaga MJ, Huebner R, Rumisha D, Binkin N, Maganu E. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus coepidemics in Botswana. Int J Tuberc Lung Dis. 1999;3:4-11.
13. Thongcharoen P, Vitayasai P, Vitayasai V, Supparatpinyo K, Tansuphaswadikul S. Opportunistic infections in AIDS/HIV infected patients in Thailand. Thai AIDS J. 1992;4:117-122.
14. Del Amo J, Petruckevitch A, Phillips AN, et al. Spectrum of disease in Africans with AIDS in London. AIDS. 1996;10:1563-1569.
15. Grant AD, Djomand G, De Cock KM. Natural history and spectrum of disease in adults with HIV/ AIDS in Africa. AIDS. 1997;11(suppl B):S43-S54.
16. Ssali FN, Kamya MR, Wabwire MF, et al. A prospective study of community-acquired bloodstream infections among febrile adults admitted to Mulago Hospital in Kampala, Uganda. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:484-499.
17. Archibald LK, den Dulk MO, Pallangyo KJ, Reller LB. Fatal Mycobacterium tuberculosis bloodstream infections in febrile hospitalized adults in Dar es Salaam, Tanzania. Clin Infect Dis. 1998;26:290-296.
18. Archibald LK, McDonald LC, Rheanpumikankit S, et al. Fever and human immunodeficiency virus infection as sentinels for emerging mycobacterial and fungal bloodstream infections in hospitalised patients >15 years old, Bangkok. J Infect Dis. 1999;180:87-92.
19. McDonald LC, Archibald LK, Rheanpumikankit S, et al. Unrecognised Mycobacterium tuberculosis bacteraemia among hospital inpatients in less developed countries. Lancet. 1999;354:1159-1163.
20. Archibald LK, McDonald LC, Nwanyanawu O, et al. A hospital-based prevalence survey of bloodstream infections in febrile patients in Malawi: implications for diagnosis and therapy. J Acquir Immune Defic Syndr Hum Retrovirol. 2000;181:1414-1420.
21. Corbett EL, Churchyard GJ, Charalambos S, et al. Morbidity and mortality in South African gold miners: impact of untreated HIV infection. Clin Infect Dis. 2002;34:1251-1258.
22. Mohar A, Romo J, Salido F, et al. The spectrum of clinical and pathological manifestations of AIDS in a consecutive series of autopsied patients in Mexico. AIDS. 1992;6:467-473.
23. Nelson AM, Perriens JH, Kapita B, et al. A clinical and pathological comparison of the WHO and CDC case definitions for AIDS in Kinshasa, Zaire: is passive surveillance valid? AIDS. 1993;7:1241-1245.
24. Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a west African city. AIDS. 1993;7:1569-1579.
25. Domoua K, N'Dhatz M, Coulibaly G, et al. Autopsy findings in 70 AIDS patients who died in a department of pneumology in Ivory Coast: impact of tuberculosis. Med Trop (Mars). 1995; 55:252-254.
26. Rana FS, Hawken MP, Mwachari C, et al. Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya. J Acquir Immune Defic Syndr. 2000;24:23-29.
27. Odhiambo JA, Borgdorff MW, Kiambih FM, et al. Tuberculosis and the HIV epidemic: increasing annual risk of infection in Kenya, 1986-1996. Am J Public Health. 1999;89:1078-1082.
28. Agerton TB, Valway SE, Blinkhorn RJ, et al. Spread of strain W, a highly drug-resistant strain of Mycobacterium tuberculosis, across the United States. Clin Infect Dis. 1999;29:85-92.
29. Moss AR, Alland D, Teizak E, et al. A city-wide outbreak of a multiple-drug-resistant strain of Mycobacterium tuberculosis in New York. Int J Tuberc Lung Dis. 1997;1:115-121.
30. Moro ML, Gori A, Errante I, et al, for the Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. AIDS. 1998;12:1095-1102.
31. Ritacco V, Di Lonardo M, Reniero A, et al. Nosocomial spread of human immunodeficiency virusrelated multidrug-resistant tuberculosis in Buenos Aires. J Infect Dis. 1997;176:637-642.
32. Goble M, Iseman MD, Madsen LA. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin. N Engl J Med. 1993;328:527-532.
33. Dye C, Williams BG. Criteria for the control of drug-resistant tuberculosis. Proc Natl Acad Sci U S A. 2000;97:8180-8185.
34. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA. 1999;282:677-686.
35. Coovadia HM, Jeena P, Wilkinson D. Childhood human immunodeficiency virus and tuberculosis co-infections: reconciling conflicting data. Int J Tuberc Lung Dis. 1998;2:844-851.
36. Joint United Nations Programme on HIV/AIDS. Report on the Global HIV/AIDS Epidemic, June 2000. Geneva, Switzerland: UNAIDS/WHO; 2000:13E.
37. World Health Organization. Global Tuberculosis Control. Geneva, Switzerland: World Health Organization; 2001. Publication WHO/CDS/TB/ 2001.287.
38. Murray CJ, Stybto K, Rouillon A. Health sector priorities review: tuberculosis. In: Jamison DT, Mosley WH, eds. Disease Control Priorities in Developing Countries. New York, NY: Oxford University Press; 1993.
39. United Nations Population Division. Comprehensive Tables. New York, NY: United Nations; 2001. World Population Prospects, 2000 Revision; vol 1.
40. United Nations Population Division. Sex and Age Distribution of the World Population. New York, NY: United Nations; 2001. World Population Prospects, 2000 Revision; vol 2.
41. Reider, HL. The Epidemiologic Basis of Tuberculosis Control Paris, France: International Union Against Tuberculosis and Lung Disease; 1999:63-87.
42. Uplekar MW, Rangan S. Private doctors and tuberculosis control in India. TuberLungDis. 1993; 74:332-337.
43. Collaborative Group for the Study of Tuberculosis in Spain. Epidemiological trends of tuberculosis in Spain from 1989 to 1992. Tuber Lung Dis. 1995;76:522-525.
44. Rose AM, Watson JM, Graham C, et al. Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998. Thorax. 2001;56:173-179.
45. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 1999. Atlanta, Ga: US Dept of Health and Human Services; 2000.
46. Centers for Disease Control and Prevention. National HIV Prevalence Surveys, 1997 (Summary). Atlanta, Ga: US Dept of Health and Human Services; 1998.
47. Malkin JE, Prazuck T, Simonnet F, et al. Tuberculosis and human immunodeficiency virus infection in west Burkina Faso: clinical presentation and clinical evolution. Int J Tuberc Lung Dis. 1997;1:68-74.
48. Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med. 1999;159:733-740.
49. Elliott AM, Halwiindi B, Hayes RJ, et al. The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. J Trop Med Hyg. 1993;96:1-11.
50. Orege PA, Fine PE, Lucas SB, et al. A case control study on human immunodeficiency virus-1 (HIV-1) infection as a risk factor for tuberculosis and leprosy in western Kenya. Tuber Lung Dis. 1993;74:377-381.
51. Van den Broek J, Borgdorff MW, Pakker NG, et al. HIV-1 infection as a risk factor for the development of tuberculosis: a case-control study in Tanzania. Int J Epidemiol. 1993;22:1159-1165.
52. Richards SB, St Louis ME, Nieburg P, et al. Impact of the HIV epidemic on trends in tuberculosis in Abidjan, Côte d'Ivoire. Tuber Lung Dis. 1995;76:11-16.
53. Shafer RW, Edlin BR. Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past decade. Clin Infect Dis. 1996;22:683-704.
54. Styblo K. Epidemiology of Tuberculosis: Selected Papers. The Hague, the Netherlands: Royal Netherlands Tuberculosis Association (KNCV); 1991.
55. Styblo K. The relationship between the risk of tuberculous infection and the risk of developing infectious tuberculosis. Bull Int Union Tuberc. 1985; 60:117-119.
56. Hilleboe HE. Post-sanatorium tuberculosis survival rates in Minnesota. Public Health Rep. 1941; 56:895-907.
57. National Tuberculosis Institute Bangalore. Tuberculosis in a rural population of South India: a five-year epidemiological study. Bull World Health Organ. 1974;51:473-488.
58. Krebs W. Die Fallen von Lungentuberkulose in der aarganuischen Heilstatte Barmelweid aus den Jahren 1912-1927. Der Aargan uischen Heilstatte Barmelweid. 1930:345-379.
59. Centers for Disease Control and Prevention. Nosocomial transmission of multidrugresistant tuberculosis among HIV-infected persons: Florida and New York, 1988-1991. MMWR Morb Mortal Wkly Rep. 1991;40:585-591.
60. Small P, Schecter G, Goodman P, Sande M, Chaisson R, Hopewell P. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med. 1991; 324:289-294.
61. Pablos-Mendez A, Sterling TR, Frieden TR. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA. 1996;276:1223-1238.
62. Palmieri F, Pellicelli AM, Girardi E, et al. Negative predictors of survival in HIV-infected patients with culture-confirmed pulmonary tuberculosis. Infection. 1999;27:331-334.
63. Shafer RW, Bloch AB, Larkin C, etal. Predictors of survival in HIV-infected tuberculosis patients. AIDS. 1996;10:269-272.
64. Whalen C, Horsburgh-CR Jr, Hom D, Lahart C, Simberkoff M, Eliner J. Site of disease and opportunistic infection predict survival in HIV-associated tuberculosis. AIDS. 1997;11:455-460.
65. Harries AD, Nyangulu DS, Kang'ombe C, et al. Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba Hospital, Malawi. Trans R Soc Trop Med Hyg. 1998; 92:343-347.
66. Ya Diul M, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS. 2001;15:143-152.
67. Ackah AN, Coulibaly D, Digbeu H, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire. Lancet. 1995; 345:607-610.
68. Greenberg AE, Lucas S, Tossou O, et al Autopsyproven causes of death in HIV-infected patients treated for tuberculosis in Abidjan, Côte d'Ivoire. AIDS. 1995;9:1251-1254.
69. Churchyard GJ, Corbett EL, Kleinschmidt I, Murray J, Smit J, De Cock KM. Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners. Int J Tuberc Lung Dis. 2000;4:705-712.
70. Stybio K. Overview and epidemiologic assessment of the current global tuberculosis situation with an emphasis on control in developing countries. Rev Infect Dis. 1989;11 (suppl 2): S339-S346.
71. Grzybowski S, Enarson DA. The fate of pulmonary tuberculosis undervarious treatment programmes. Bull Int Union Tuberc. 1978;53:70-75.
72. Nunn P, Kibuga D, Gathua S, et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet. 1991;337:627-630.
73. Johnson JL, Okwera A, Vjecha MJ, et al. Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis. Int J Tuberc Lung Dis. 1997;1:446-453.
74. Nunn P, Brindle R, Carpenter L, et al. Cohort study of human immunodeficiciency virus infection in patients with tuberculosis in Nairobi, Kenya. Am J Respir Crit Care Med. 1992;146:849-854.
75. Brindle RJ, Nunn PP, Batchelor BI, et al. Infection and morbidity in patients with tuberculosis in Nairobi, Kenya. AIDS. 1993;7:1469-1474.
76. Okwera A, Whalen C, Byewaso F, et al., Randomised trial of thiacetazone and rifampicincontaining regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet. 1994;344:1323-1328.
77. Elliott AM, Halwiindi B, Hayes RJ, et al. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Trans R Soc Trop Med Hyg. 1995;89:78-82.
78. Kassim S, Sassan MM, Ackah A, et al. Two-year follow-up of persons with HIV-1 - and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS. 1995;9:1185-1191.
79. Van den Broek J, Mfinanga S, Moshiro C, O'Brien R, Mugomela A, Lefi M. Impact of human immunodeficiency virus infection on the outcome of treatment and survival of tuberculosis patients in Mwanza, Tanzania. Int J Tuberc Lung Dis. 1998;2:547-552.
80. Wiktor SZ, Sassan MM, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Lancet. 1999;353:1469-1475.
81. Connolly C, Reid A, Davies G, Sturm W, McAdam KP, Wilkinson D. Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. AIDS. 1999;13:1543-1547.
82. Girardi E, Palmeieri F, Cingolani A, et al. Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26:326-331.
83. Conti S, Masocco M, Pezzotti P, et al. Differential impact of combined antiretroviral therapy on the survival of Italian patients with specific AIDS-defining illnesses. J Acquir Immune Defic Syndr. 2000;25:451-458.
84. Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS. 2002;16:75-83.
85. Mallory KM, Churchyard GJ, Kleinschmidt I, De Cock KM, Corbett EL. Impact of HIV infection on rates of recurrence after treatment for tuberculosis in South African gold miners. IntJ Tuberc Lung Dis. 2000;4:455-462.
86. Connolly C, Davies GR, Wilkinson D. Impact of the human immunodeficiency virus epidemic on mortality among adults with tuberculosis in rural South Africa, 1991-1995. Int J Tuberc Lung Dis. 1998;2:919-925.
87. Kang'ombe C, Harries AD, Banda H, et al. High mortality rates in tuberculosis patients in Zomba Hospital, Malawi, during 32 months of follow-up. Trans R Soc Trop Med Hyg. 2000;94:305-309.
88. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet. 2001;358:1687-1693.
89. Driver CR, Munsiff SS, Li J, Kundamal N, Osahan SS. Relapse in persons treated for drugsusceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin Infect Dis. 2001;33:1762-1769.
90. Sterling TR, Alwood K, Gachuhi R, et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS. 1999;13:1899-1904.
91. Uplekar M, Juvekar S, Morankar S, Rafigan S, Nunn P. Tuberculosis patients and practitioners in private clinics in India. Int J Tuberc Lung Dis. 1998;2:324-329.
92. De Cock KM, Soro B, Coulibaly IM, Lucas SB. Tuberculosis and HIV infection in sub-Saharan Africa. JAMA. 1992;268:1581-1587.
93. Banda H, Kang'ombe C, Harries AD, et al. Mortality rates and recurrent rates of tuberculosis in patients with smear-negative pulmonary tuberculosis and tuberculous pleural effusion who have completed treatment. Int J Tuberc Lung Dis. 2000;4:968-974.
94. Harries AD, Nyirenda TE, Baneriee A, Boeree MJ, Salaniponi FM. Treatment outcome of patients with smear-negative and smear-positive pulmonary tuberculosis in the National Tuberculosis Control Programme, Malawi. Trans R Soc Trop Med Hyg. 1999;93:443-446.
95. Harries AD, Nyangulu DS, Banda H, et al. Efficacy of an unsupervised ambulatory treatment regimen for smear-negative pulmonary tuberculosis and tuberculous pleural effusion in Malawi. Int J Tuberc Lung Dis. 1999;3:402-408.
96. Hargreaves NJ, Kadzakumanja O, Whitty CJ, Salaniponi FM, Harries AD, Squire SB. 'Smear-negative' pulmonary tuberculosis in a DOTS programme: poor outcomes in an area of high HIV seroprevalence. Int J Tuberc Lung Dis. 2001;5:847-854.
97. World Health Organisation. International Union Against Tuberculosis and Lung Diseases. Royal Netherlands Tuberculosis Association: revised international definitions of tuberculosis control. Int J Tuberc Lung Dis. 2001;5:213-215.
98. The World Health Report 2002. Geneva, Switzerland: World Health Organization; 2002. Available at: http://www.who.int/whr/2002/en.
99. Tanzania Tuberculin Survey Collaboration. Tuberculosis control in the era of the HIV epidemic: risk of tuberculosis infection in Tanzania, 1983-1998. Int J Tuberc Lung Dis. 2001;5:103-112.
100. Glynn JR, Warndorff DK, Malema SS, et al. Tuberculosis: associations with HIV and socioeconomic status in rural Malawi. Trans R Soc Trop Med Hyg. 2000;94:500-503.
101. Range N, Ipuge YA, O'Brien RJ, et al. Trend in HIV prevalence among tuberculosis patients in Tanzania, 1991-1998. Int J Tuberc Lung Dis. 2001;5:405-412.
102. US Bureau of the Census, Population Division, International Programs Center. HIV/AIDS Surveillance Database, July 2000. Washington, DC: US Bureau of the Census; 2000.
103. World Health Organization. Global Tuberculosis Control: Surveillance, Planning and Financing. Geneva, Switzerland: World Health Organization; 2002. Publication WHO/CDS/TB/2002.295.
104. Quigley MA, Mwinga A, Hosp M, et al. Longterm effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS. 2001;15:215-222.
105. Jones JL, Hanson DL, Dworkin MS, De Cock KM, for the Adult/Adolescent Spectrum of HIV Disease Group. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. Int J Tuberc Lung Dis. 2000;4:1026-1031.
106. Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS. 2000;14:1985-1991.
107. Martin V, Cayla JA, Bolea A, Castilla J. Mycobacterium tuberculosis and human immunodeficiency virus co-infection in intravenous drug users on admission to prison. IntJ Tuberc Lung Dis. 2000;4:41-46.
108. Smith DK, Gwinn M, Selik RM, et al. HIV/AIDS among African Americans: progress or progression? AIDS. 2001;14:1237-1248.
109. Espinal MA, Laszlo A, Simonsen L, et al, for the World Health Organization-International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. Global trends in resistance to antituberculosis drugs. N Engl J Med. 2001; 344:1294-1303.
110. Dehne KL, Pokrovskiy V, Kobyshcha Y, Schwartlander B. Update on the epidemics of HIV and other sexually transmitted infections in the newly independent states of the former Soviet Union. AIDS. 2000;14(suppl 3):S75-S84.
111. Punnotok J, Shaffer N, Naiwatanakul T, et al. Human immunodeficiency virus-related tuberculosis and primary drug resistance in Bangkok, Thailand. Int J Tuberc Lung Dis. 2000;4:537-543.
112. Dye C, Espinal MA, Watt C, Mbiaga C, Williams BG. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis. 2001;185:1197-1202.
113. Corbett EL, Churchyard GJ, Clayton TC, etal. HIV infection and silicosis: the impact of two potent risk factors on mycobacterial disease incidence in South African miners. AIDS. 2000;14:2759-2768.
114. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA. 1992;268:504-509.
115. Klein RS, Gourevitch MN, Teeter R, Schoenbaum EE. The incidence of tuberculosis in drug users with small tuberculin reaction sizes. Int J Tuberc Lung Dis. 2001;5:707-711.
116. Ferreira MM, Ferrazoli L, Palaci M, et al. Tuberculosis and HIV infection among female inmates in Sao Paulo, Brazil: a prospective cohort study. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:177-183.
117. Braun MM, Badi N, Ryder RW, et al. A retrospective cohort study of the risk of tuberculosis among women of childbearing age with HIV infection in Zaire. Am Rev Respir Dis. 1991;143:501-504.
118. Allen S, Batungwanayo J, Kerlikowske K, et al. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am Rev Respir Dis. 1992;146:1439-1444.
119. Leroy V, Msellati P, Lepage P, et al. Four years of natural history of HIV-1 infection in African women: a prospective cohort study in Kigali (Rwanda), 1988-1993. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9:415-421.
120. Reider HL, Cauthen GM, Comstock GW, Snider DE Jr. Epidemiology of tuberculosis in the United States. Epidemiol Rev. 1989;11:79-98.
121. Dye C, Zhao F, Scheele S, Williams BG. Evaluating the impact of tuberculosis control: number of deaths prevented by short-course chemotherapy in China. Int J Epidemiol. 2000;29:564.
122. Suarez P, Watt CJ, Alarcon E, et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis. 2001;184:473-478.
123. Celentano DD, Nelson KE, Lyles CM, et al. Decreasing incidence of HIV and sexually transmitted diseases in young Thai men: evidence for success of the HIV/AIDS control and prevention program. AIDS. 1998;12:F29-F36.
124. Merson MH, Dayton JM, O'Reilly K. Effectiveness of HIV prevention interventions in developing countries. AIDS. 2000;14(suppl):S68-S84.
125. Grosskurth H, Gray R, Hayes R, Mabey D, Wawer M. Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials. Lancet. 2000;355:1981-1987.
126. The Voluntary HIV-1 Counseling and Testing Efficacy Study Group. Efficacy of voluntary HIV-1 counselling and testing in individuals and couples in Kenya, Tanzania, and Trinidad: a randomised trial. Lancet. 2000;356:103-112.
127. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City: turning the tide. N Engl J Med. 1995;333:229-333.
128. De Cock KM, Chaisson RE. Will DOTS do it? a reappraisal of tuberculosis control in countries with high rates of HIV infection. IntJ Tuberc Lung Dis. 1999;3:457-465.